...
首页> 外文期刊>International Journal of Clinical and Experimental Pathology >An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: I. cytokeratin profile in 42 cases
【24h】

An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: I. cytokeratin profile in 42 cases

机译:胃和结直肠原发性印戒细胞癌的免疫组织化学研究:I.细胞角蛋白谱42例

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Expression of cytokeratin (CK) profiles in primary signet-ring cell carcinoma (SRCC) of the stomach and colorectum have rarely reported; only two such studies are present in the world literature. Herein, an immunohistochemical study on cytokeratin (CK) expression was performed in 42 cases of primary SRCC of the stomach (30 cases) and colorectum (12 cases). SRCC was defined as an adenocarcinoma in which more than 50% adenocarcinoma cells showed SRCC phenotype with prominent intracytoplasmic mucins. In the gastric SRCC, the expression of CK was as follows; CK AE1/3 (30/30, 100%) CK CAM5.2 (30/30, 100%), CK 34BE12 (0/30, 0%), CK5/6 (2/30, 7%), CK7 (26/30, 89%), CK8 (12/30, 40%), CK14 (0/30, 0%), CK18 (30/30, 100%), CK19 (2/30, 7%), and CK20 (3/30, 10%). In the colorectal SRCC, the expression of CK was as follows; CK AE1/3 (12/12, 100%) CK CAM5.2 (12/12, 100%), CK 34BE12 (0/12, 0%), CK5/6 (0/12, 10%), CK7 (2/12, 17%), CK8 (3/12, 25%), CK14 (0/12, 0%), CK18 (12/12, 100%), CK19 (7/12, 58%), and CK20 (8/12, 67%). A statistical analysis showed that significant differences of CK expression between the gastric SRCC and colorectal SRCC were observed in CK7 (stomach 67% vs. colorectum 17%), CK19 (7% vs. 42%) and CK20 (13% vs. 67%); gastric SRCC tended to express CK7, but not CK19 and CK20, while colorectal SRCC tended to express CK19 and CK20, but not CK7. In gastric SRCC, CK7+/CK20- pattern was as follows: CK7+/CK20- (24/30, 81%), CK7+/CK20+ (2/30, 6%), CK7-/CK20+ (1/30, 3%), and CK7-/CK20- (3/30, 10%). CK7/CK19 patterns in gastric SRCC were as follows; CK7+/CK19- (25/30, 83%) CK7+/CK19+ (1/30, 3%), CK7-/CK19+ (1/30, 3%), CK7-/CK19- (3/30, 10%). In colorectal SRCC, the CK7/CK20 patterns were as follows: CK7+/CK20- (2/12, 17%), CK7+/CK20+ (0/12, 0%), CK7-/CK20+ (8/12, 66%), and CK7-/CK20- (2/12, 17%). The CK7/CK19 pattern in colorectal SRCC was as follows; CK7+/CK19- (1/12, 8%), CK7+/CK19+ (1/12, 8%), CK7-/CK19+ (6/12, 50%), and CK7-/CK19- (4/12, 34%). Statistical data indicated that CK7+/CK20- and CK7+/CK19- patterns were significantly prevalent in gastric SRCC, and CK7-/CK20+, CK7-/CK19+ and CK7-/CK20- patterns dominated significantly in colorectal SRCC. CK expression has been studied largely in terms of CD7/CK20 expression pattern in various carcinomas. The present study provided possible usefulness of CK7/19 expression status in various carcinomas including SRCC.
机译:胃和结肠直肠原发性印戒细胞癌(SRCC)中细胞角蛋白(CK)的表达很少见;世界文学中只有两项这样的研究。在此,对42例胃原发性SRCC(30例)和结直肠癌(12例)的细胞角蛋白(CK)表达进行了免疫组织化学研究。 SRCC被定义为一种腺癌,其中超过50%的腺癌细胞显示出SRCC表型以及突出的胞浆内粘蛋白。在胃SRCC中,CK的表达如下: CK AE1 / 3(30/30,100%)CK CAM5.2(30/30,100%),CK 34BE12(0/30,0%),CK5 / 6(2/30,7%),CK7( 26/30,89%),CK8(12/30,40%),CK14(0/30,0%),CK18(30/30,100%),CK19(2/30,7%)和CK20 (3 / 30,10%)。在大肠SRCC中,CK的表达如下: CK AE1 / 3(12/12,100%)CK CAM5.2(12/12,100%),CK 34BE12(0/12,0%),CK5 / 6(0/12,10%),CK7( 2/12,17%),CK8(3/12,25%),CK14(0/12,0%),CK18(12/12,100%),CK19(7/12,58%)和CK20 (8/12,67%)。统计分析表明,在CK7(胃67%对结直肠17%),CK19(7%对42%)和CK20(13%对67%)中,胃SRCC和结直肠SRCC之间的CK表达存在显着差异。 );胃SRCC倾向于表达CK7,而不表达CK19和CK20,而大肠SRCC倾向于表达CK19和CK20,而不表达CK7。在胃SRCC中,CK7 + / CK20-模式如下:CK7 + / CK20-(24/30,81%),CK7 + / CK20 +(2/30,6%),CK7- / CK20 +(1/30,3%) ,以及CK7- / CK20-(3/30,10%)。胃SRCC中的CK7 / CK19模式如下: CK7 + / CK19-(25/30,83%)CK7 + / CK19 +(1/30,3%),CK7- / CK19 +(1/30,3%),CK7- / CK19-(3/30,10%) 。在结直肠SRCC中,CK7 / CK20模式如下:CK7 + / CK20-(2/12,17%),CK7 + / CK20 +(0/12,0%),CK7- / CK20 +(8/12,66%) ,和CK7- / CK20-(2/12,17%)。大肠SRCC中的CK7 / CK19图谱如下: CK7 + / CK19-(1/12,8%),CK7 + / CK19 +(1/12,8%),CK7- / CK19 +(6/12,50%)和CK7- / CK19-(4/12,34 %)。统计数据表明,CK7 + / CK20-和CK7 + / CK19-模式在胃SRCC中非常普遍,而CK7- / CK20 +,CK7- / CK19 +和CK7- / CK20-模式在大肠SRCC中占主导。 CK表达已在各种癌症中大量研究了CD7 / CK20表达模式。本研究提供了CK7 / 19表达状态在包括SRCC在内的各种癌中的可能有用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号